Theralase Technologies (CVE:TLT) Trading Up 3.7% - Still a Buy?

Key Points

• Shares rose 3.7% to C$0.28 on Friday with about 108,776 shares traded (roughly 50% below average); the 50‑day and 200‑day simple moving averages are C$0.26 and C$0.21, respectively.
• Theralase is a clinical-stage pharmaceutical company developing light-activated photodynamic compounds (PDCs) and patented super‑pulsed laser technology for cancer, infectious disease and chronic pain applications.
• Financial snapshot: market capitalization C$74.17 million, negative PE (-15.56), current ratio 0.83, quick ratio 3.40 and a debt‑to‑equity ratio of 29.26.

Shares of Theralase Technologies Inc. (CVE:TLT - ) rose 3.7% during trading on Friday . The company traded as high as C$0.28 and last traded at C$0.28. Approximately 108,776 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 217,092 shares. The stock had previously closed at C$0.27.

Theralase Technologies Trading Up 3.7%

The company has a market capitalization of C$74.17 million, a PE ratio of -15.56 and a beta of -0.29. The company has a current ratio of 0.83, a quick ratio of 3.40 and a debt-to-equity ratio of 29.26. The business's 50-day simple moving average is C$0.26 and its two-hundred day simple moving average is C$0.21.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.